Argenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Biosciences buy.
Argenx shutters Sjogren’s study, losing blockbuster expansion opportunity for Vyvgart